Date: 2014-04-10
Type of information: Licensing agreement
Compound: vaccine for the prevention of Japanese encephalitis (IXIARO®)
Company: Valneva (France - Austria) Adimmune Corporation (Taiwan)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
Disease: Japanese encephalitis
Details: * On April 10, 2014, European biotechnology company Valneva has announced that it has granted vaccine manufacturer Adimmune Corporation certain exclusive rights to its Japanese encephalitis (JE) vaccine in Taiwan. Adimmune will be entitled to register and commercialize Valneva´s JE vaccine under a local trade name and to develop, manufacture and commercialize such a vaccine from bulk product delivered by Valneva. Financial terms for the delivery of the vaccine by Valneva were not disclosed.
Financial terms:
Latest news: * On January 11, 2016, Valneva announced that vaccine manufacturer Adimmune was granted marketing approval for Valneva’s Japanese encephalitis (JE) vaccine by the Taiwanese Food & Drug Administration (TFDA). The product is expected to be marketed in Taiwan under the trade name Jeval®. This approval follows the agreement signed in 2014 between Valneva and Adimmune granting Adimmune the right to commercialize Jeval® in Taiwan, including the right to
locally fill and pack Jeval® by using bulk product delivered by Valneva.
In order to supply large quantities of Jeval® for Taiwan’s national immunization program at a competitive cost base, Adimmune intends to establish a local fill-and-finish of the vaccine within the next two years.
